Phase 1 of NIH-SBIR Grant project is complete
ANN ARBOR, Mich. , July 7, 2022 /PRNewswire/ -- Today Xoran Technologies announces that it has completed the Phase 1 milestones of the SBIR project, funded by the NIH and NINDS to demonstrate feasibility of a highly portable and affordable cranial computed tomography perfusion (CT-P) device. "We are proud of this milestone and grateful to NIH and NINDS for their support," states William van Kampen , Xoran CTO and principal investigator on the project. "Our goal is that in the future this technology will help expedite the front-line evaluation and triage of cerebral stroke victims."
in the future, this technology will help expedite the front-line evaluation and triage of cerebral stroke victims.
In 2020 Xoran received this Small Business Innovation Research (SBIR) grant award from the National Institutes of Health (NIH) and the National Institute of Neurological Disorders and Stroke (NINDS). The aims of Phase 1 were both to develop a compact, fast-rotating gantry and to confirm time-resolved contrast imaging feasibility—all to be incorporated in a future device compact enough to be transported by two or less people in a mid-sized civilian or military vehicle, or an ambulance.
"What we know about stroke is that 'time is brain.' Previously we had few effective therapies for stroke, but in the recent years we have developed extremely robust and successful therapies, as long as we can diagnose and treat the problem in its very early stages. That is why this project is so exciting," says neurosurgeon William Gormley , MD, MPH, MBA. "Expanding access by setting-up mobile CT-Perfusion scanners that can potentially be deployed in existing ambulances and directly reach affected patients where they are first seen, changes everything. The rapid screening, early detection and diagnosis of cerebral ischemia means we will be able to reverse strokes, save more brain and prevent major morbidity and mortality from this devastating disease."
Indeed, the combined tens of thousands of ambulances, urgent care centers, and homes for elder care in the United States alone could benefit from an affordable point-of-care CT-P device. Deploying this future device in cities and rural areas means many more individuals suffering from acute stroke can be rapidly evaluated and treated within the beneficial window, thereby reducing disability and improving functional independence and quality of life for affected individuals.
Complementary to this project is a patent that Xoran recently received for a modular computed tomography (CT) system assembly. "This revolutionary cone beam CT configuration paired with our twenty-and-counting current patents unlocks a plethora of new capabilities. The technology is just the beginning of a new generation of Xoran's point-of-care (POC) imaging devices," explains Misha Rakic , Xoran CEO. "In the future, this advancement means that ultra-compact CT can fit into existing ambulances without the need for a dedicated mobile stroke unit for early stroke detection. It could also be used by first responders in front-line and natural disaster scenarios as well as by military in the battlefield. The possibilities for highly deployable head CT are virtually limitless."
Over 795,000 individuals suffer from strokes each year in the U.S. alone. When an individual is suffering from acute stroke, time is of the essence; however, it is critically important to assess the type of stroke as well as the amount and location of potentially recoverable brain tissue to determine the appropriate treatment routing and priority to achieve the best outcome for that individual.
Since 2001, Xoran has been the pioneer and market leader in medical point-of-care cone beam CT systems. Last year, Xoran celebrated its 20th anniversary, a significant milestone within the ENT and allergy community. Xoran's flagship product, MiniCAT—a low dose upright CBCT solution, is a vital in-office tool for otolaryngologists to identify and diagnose sinus and ear disease directly where the clinician is seeing the patient. Today there are over 1,000 Xoran CT systems installed globally.
Xoran is based in Ann Arbor, Michigan . For more information visit www.xorantech.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/xoran-announces-milestone-towards-future-ct-perfusion-device-301581828.html
Despite recent investor skepticism, the Phase 3 COVID-19 results for Veru Inc's (NASDAQ: VERU) sabizabulin published in the New England Journal of Medicine "addressed most concerns," Jefferies writes. The analyst sees the data as "further derisking" Veru's COVID opportunity and reiterates a Buy rating on the shares with a $55 price target. The data likely signals an FDA Emergency Use Authorization in 30 days, Howerton contends. Related: Veru Seeks FDA Emergency Use Nod For Its COVID-19 Treatment
Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients ages 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
The company said in May that it and its Big Pharma partner were reviewing one of its two Alzheimer's Disease-focused programs.
At Illumina, we are driven by the power of genomics to positively impact the world and shape a more sustainable and equitable future for all.
The job cuts will save the company more than $15 million annually, it said, with upfront restructuring costs of $4.2 million.
Yahoo Finance health reporter Anjalee Khemlani outlines the events surrounding the FDA's ban on Juul products and e-cigarettes, as well as Pfizer's Paxlovid COVID-19 treatment pill receiving an Emergency Use Authorization from the FDA.
The 34,000-square-foot facility will allow Kiromic BioPharma to begin a cell therapy clinical trial for a product candidate by the end of the year.
The myth that cannabis use leads to violence has long been present in American politics
Less than eight weeks ago, the Florida Department of Health reported the state’s first presumptive case of monkeypox — a viral disease that was once rare in the United States.
The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory route used by the companies for Aduhelm.
While the daily averages of new COVID-19 cases and deaths remained in relatively tight ranges, hospitalizations jumped to a four-month high, and the positivity rate of tests climbed to a five-month high, as the omicron subvariant BA.5 continued to spread.
Yahoo Finance's health care reporter Anjalee Khemlani breaks down the latest health news, including risks from the BA.5 and BA.4 COVID subvariants and giant African snails that have been spotted in Florida.
During a two-day conference in late June, policy advisors to the FDA and medical professionals discussed the future of xenotransplantation and "most attendees agreed that human trials are needed to help answer the most pressing research questions."
Long-term exposure to high heat can become lethal. Mark Wilson/Getty ImagesHeat waves are becoming supercharged as the climate changes – lasting longer, becoming more frequent and getting just plain hotter. One question a lot of people are asking is: “When will it get too hot for normal daily activity as we know it, even for young, healthy adults?” The answer goes beyond the temperature you see on the thermometer. It’s also about humidity. Our research shows the combination of the two can get da
The FDA announced Wednesday that state-licensed pharmacists in the US would be able to prescribe Pfizer's Paxlovid COVID-19 pill for eligible patients as cases continue to rise.
Digital health solutions, including remote patient monitoring and telemedicine, help expand healthcare access
More than half of U.S. women who received a uterus through a transplant went on to have successful pregnancies, a new study shows. Between 2016 and 2021, 33 women received uterus transplants in the United States and so far 19 of them, or 58%, have delivered a total of 21 babies, researchers reported on Wednesday in JAMA Surgery. "Uterus transplant should be considered a clinical reality in the U.S.," the researchers wrote.
Biophilic-designed communities help promote wellness of older adults by creating environments that respond to humans' love of life or nature.
Today, the more-infectious Omicron BA.5 subvariant is officially the dominant Covid strain in the U.S. Up until how, BA.5 has been tied to its sister Omicron subvariant, BA.4, as both had steadily outcompeted BA.2.12.1 — which itself had been driving cases for the past month or so. After the original Omicron variant appeared on U.S. […]
Doctors caution that rest is an important part of weathering a COVID-19 infection.